Skip to main content
Equibles
ADCT logo

ADCT · ADC Therapeutics SA · Earnings Call Transcripts & Audio

Track ADCT — free

Use ADCT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADCT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.07 -0.04 (-3.60%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$136.60M
Shares
127.67M

ADC Therapeutics SA Earnings Call Transcripts

Quarterly earnings calls for ADC Therapeutics SA (ADCT), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲480.5% $76.32M −$50.61M '22 Q3 22-09-30 ▲310.3% $69.80M −$25.48M '22 Q4 22-12-31 ▼59.2% $18.99M −$59.37M '23 Q1 23-03-31 ▲11.5% $19.28M −$48.92M '23 Q2 23-06-30 ▼81% $14.49M −$46.73M '23 Q3 23-09-30 ▼75.9% $16.79M −$85.03M '23 Q4 24-01-04 ▼4.9% $18.05M −$46.61M '24 Q1 24-05-06 ▼9.7% $17.41M −$36.54M '24 Q2 24-08-06 ▲27.4% $18.46M −$43.97M '24 Q3 24-11-07 ▲0.7% $16.91M −$30.73M '24 Q4 25-01-13 ▲27.6% $23.03M −$38.60M '25 Q1 25-05-14 ▲8.2% $18.84M −$56.65M '25 Q2 25-08-12 ▼11% $16.43M −$40.97M '25 Q3 25-11-03 ▲36.4% $23.06M −$6.41M '25 Q4 26-03-10 ▼9.5% $20.85M −$32.97M '26 Q1 26-06-03 LATEST ▲2.2% $19.25M −$16.57M '26 Q2 26-08-13
Earnings call
FY26 · Q2
2026-08-13
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call
Revenue
$19.25M
▲ 2.2% YoY
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-06-03
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
Positive tone ZYNLONTA Commercial Performance LOTIS-5 Confirmatory Trial Cost Management and Cash Runway
Revenue
$20.85M
▼ 9.5% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-10
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript
Confident tone LOTIS-5 trial and 2L expansion ZYNLONTA commercial performance in 3L+ DLBCL Indolent lymphoma opportunity
Revenue
$23.06M*
▲ 36.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript
Positive tone LOTUS V Phase III confirmatory trial ZENLATA commercial performance and stability DLBCL treatment landscape segmentation
Revenue
$16.43M
▼ 11% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript
Confident tone LOTIS-7 bispecific combination data ZYNLONTA commercial performance LOTIS-5 confirmatory Phase 3
Revenue
$18.84M
▲ 8.2% YoY
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript
Positive tone LOTIS-7 ZYNLONTA plus glofitamab combination Upcoming medical congress data presentations ZYNLONTA commercial performance and 3L+ DLBCL positioning
Revenue
$23.03M
▲ 27.6% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript
Confident tone ZYNLONTA Commercial Performance LOTIS-5 Phase 3 Trial Indolent Lymphoma Expansion (FL/MZL)
Revenue
$16.91M*
▲ 0.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript
Positive tone ZYNLONTA commercial performance and DLBCL positioning LOTIS-7 ZYNLONTA plus glofitamab combination LOTIS-5 Phase III confirmatory study
Revenue
$18.46M
▲ 27.4% YoY
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript
Positive tone ZYNLONTA commercial performance Hematology pipeline expansion Solid tumor pipeline
Revenue
$17.41M
▼ 9.7% YoY
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript
Confident tone ZYNLONTA commercial performance LOTIS-7 ZYNLONTA plus bispecifics LOTIS-5 Phase 3 confirmatory study
Revenue
$18.05M
▼ 4.9% YoY
Diluted EPS
$-0.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-04
ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript
Positive tone ZYNLONTA commercial performance Pipeline expansion and earlier-line opportunities Competitive landscape and bispecifics
Revenue
$16.79M*
▼ 75.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
ADC Therapeutics SA (ADCT) Q3 2023 Earnings Call Transcript
Revenue
$14.49M
▼ 81% YoY
Diluted EPS
$-0.57
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
ADC Therapeutics SA (ADCT) Q2 2023 Earnings Call Transcript
Revenue
$19.28M
▲ 11.5% YoY
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
ADC Therapeutics SA (ADCT) Q1 2023 Earnings Call Transcript
Revenue
$18.99M
▼ 59.2% YoY
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
ADC Therapeutics SA (ADCT) Q4 2022 Earnings Call Transcript
Revenue
$69.80M*
▲ 310.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
ADC Therapeutics SA (ADCT) Q3 2022 Earnings Call Transcript
Revenue
$76.32M
▲ 480.5% YoY
Diluted EPS
$-0.65
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
ADC Therapeutics SA (ADCT) Q2 2022 Earnings Call Transcript
Revenue
$17.29M
▲ 359.9% YoY
Diluted EPS
$-0.84
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
ADC Therapeutics SA (ADCT) Q1 2022 Earnings Call Transcript
Revenue
$46.50M
Diluted EPS
$-0.22
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
ADC Therapeutics SA (ADCT) Q4 2021 Earnings Call Transcript
Revenue
$17.01M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript
Revenue
$13.15M
Diluted EPS
$-0.93
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
ADC Therapeutics SA (ADCT) Q2 2021 Earnings Call Transcript
Revenue
$3.76M
Diluted EPS
$-0.95
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
ADC Therapeutics SA (ADCT) Q1 2021 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.67
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
ADC Therapeutics SA (ADCT) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
ADC Therapeutics SA (ADCT) Q3 2020 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.29
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
ADC Therapeutics SA (ADCT) Q2 2020 Earnings Call Transcript
Revenue
$
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 earnings calls
Key facts CIK 1771910 CUSIP H0036K147 13F (30d) 40 filings 40 filers Visit website Investor relations